Farrell Simon's Insider Trades & SAST Disclosures
Farrell Simon's most recent trade in Trevi Therapeutics Inc was a trade of 76,963 Common Stock done at an average price of $6.7 . Disclosure was reported to the exchange on March 10, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Farrell Simon.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Trevi Therapeutics Inc | Farrell Simon | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 6.73 per share. | 10 Mar 2025 | 76,963 | 81,250 (0%) | 0% | 6.7 | 517,776 | Common Stock |
| Trevi Therapeutics Inc | Farrell Simon | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 63,813 | 11,187 | - | - | Stock Option (right to buy) | |
| Trevi Therapeutics Inc | Farrell Simon | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.91 per share. | 10 Mar 2025 | 63,813 | 126,963 (0%) | 0% | 3.9 | 249,509 | Common Stock |
| Trevi Therapeutics Inc | Farrell Simon | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2025 | 38,400 | 38,400 | - | - | Performance Stock Option (right to buy) | |
| Trevi Therapeutics Inc | Farrell Simon | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 31,250 | 18,750 | - | - | Stock Option (right to buy) | |
| Trevi Therapeutics Inc | Farrell Simon | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.51 per share. | 10 Mar 2025 | 31,250 | 158,213 (0%) | 0% | 0.5 | 15,969 | Common Stock |
| Trevi Therapeutics Inc | Farrell Simon | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.21 per share. | 10 Mar 2025 | 17,500 | 63,150 (0%) | 0% | 3.2 | 56,175 | Common Stock |
| Trevi Therapeutics Inc | Farrell Simon | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 17,500 | 0 | - | - | Performance Stock Option (right to buy) | |
| Trevi Therapeutics Inc | Farrell Simon | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 7.15 per share. | 10 Mar 2025 | 4,350 | 76,900 (0%) | 0% | 7.1 | 31,102 | Common Stock |
| Trevi Therapeutics Inc | Farrell Simon | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2025 | 225,500 | 225,500 | - | - | Stock Option (right to buy) | |
| Trevi Therapeutics Inc | Farrell Simon | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 175,000 | 175,000 | - | - | Stock Option (right to buy) | |
| Trevi Therapeutics Inc | Farrell Simon | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jun 2023 | 6,250 | 50,000 | - | - | Stock Option (right to buy) | |
| Trevi Therapeutics Inc | Farrell Simon | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.51 per share. | 20 Jun 2023 | 6,250 | 45,650 (0%) | 0% | 0.5 | 3,194 | Common Stock |
| Trevi Therapeutics Inc | Farrell Simon | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Mar 2023 | 18,750 | 56,250 | - | - | Stock Option (right to buy) | |
| Trevi Therapeutics Inc | Farrell Simon | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.51 per share. | 07 Mar 2023 | 18,750 | 39,400 (0%) | 0% | 0.5 | 9,581 | Common Stock |
| Trevi Therapeutics Inc | Farrell Simon | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2023 | 100,000 | 100,000 | - | - | Stock Option (right to buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges